Lipoprotein(a): The Inherited Risk Number Few People Test

Someone has a heart attack in their forties. Their cholesterol was checked, and it was fine. Their blood pressure was normal, they had never smoked, and their weight was unremarkable. The family has a pattern of early heart disease that nobody has ever explained, and the standard risk calculators put them in a low-risk band right up until the event.

In a proportion of such cases the missing piece is a lipoprotein particle that a routine lipid panel does not measure and most people have never heard of. Lipoprotein(a), usually written Lp(a) and spoken as “L-P-little-a”, is a low-density lipoprotein particle carrying an extra protein attached to it. That extra protein changes what the particle does in the artery wall, and the amount of it circulating in a given person is set almost entirely by inherited genetics rather than by diet, exercise or the things that move ordinary cholesterol.

Because it is genetically determined, it behaves differently from every other lipid measurement. It does not need repeating year after year. It does not respond meaningfully to lifestyle change. And it explains why a small but substantial fraction of people develop early arterial disease with an otherwise clean risk profile.

What Makes Lipoprotein(a) Structurally Unusual

Lipoproteins are particles that carry fat through blood, which is watery and does not dissolve fat. Each consists of a core of cholesterol and triglyceride wrapped in a shell of phospholipid and protein, and the identity of the protein determines where the particle goes and what receptors recognise it.

Lipoprotein(a) begins as an ordinary low-density lipoprotein particle, complete with its usual structural protein, apolipoprotein B. What makes it different is a second protein, apolipoprotein(a), bound to the first by a covalent link. That addition creates a particle that behaves partly like LDL and partly like something else entirely.

The something else is the interesting part. Apolipoprotein(a) is structurally similar to plasminogen, the precursor of the enzyme that dissolves blood clots. Both proteins are built from repeated looped domains, and the resemblance is close enough that lipoprotein(a) can occupy sites where plasminogen would otherwise bind. The consequence is that the particle carries a plausible mechanism for impeding clot breakdown, in addition to whatever it does as a cholesterol carrier.

It has a third property as well. Lipoprotein(a) preferentially carries oxidised phospholipids, which are potent drivers of inflammation in the artery wall. This gives it a route to promoting plaque development that is distinct from simple cholesterol deposition.

So a single particle plausibly contributes to three processes at once: depositing cholesterol in the artery wall as LDL does, promoting local inflammation, and interfering with the dissolution of clots. Which dominates is not settled, and the contributions may differ between arterial disease and narrowing of the aortic valve, where lipoprotein(a) is also implicated. Its physiological purpose, if it has one, remains unclear.

Why Levels Are Set Largely by Genetics

Most lipid measurements are the output of a system responding to diet, weight, activity, alcohol, thyroid function and medication. Lipoprotein(a) is not.

The concentration in a given person is determined predominantly by inherited variation at the gene encoding apolipoprotein(a). The dominant influence is a length polymorphism: the gene contains a variable number of repeated segments, and the number of repeats a person inherits is inversely related to how much of the protein reaches the circulation. Fewer repeats produce a smaller protein that is secreted more efficiently and results in higher levels. More repeats produce a larger protein that is handled less efficiently and results in lower levels. Additional variation elsewhere in the gene modifies this further.

The practical consequences are unusual. A person’s level is essentially established at conception and reaches its adult value in early childhood. It remains broadly stable thereafter, unlike LDL cholesterol which drifts with weight and age. Diet has little effect. Exercise has little effect. Weight loss has little effect. This is genuinely different from the rest of the lipid panel, and it changes the whole logic of what testing and follow-up should look like.

The distribution across a population is also unusual. Rather than a neat bell curve, levels are heavily skewed, with most people at the lower end and a long tail extending to very high values. Roughly one person in five carries a level considered elevated, which makes this one of the more common inherited risk factors in existence. Distributions also differ between ancestry groups, with populations of African ancestry showing higher average levels, a difference that complicates the use of a single universal threshold.

Because inheritance is straightforward, an elevated level in one family member has direct implications for first-degree relatives, which is why cascade testing within families is an efficient way of finding affected people.

Mass Versus Molar Measurement Confusion

Here is where reports become genuinely confusing, and the confusion has real consequences for interpretation.

Lipoprotein(a) can be reported in two fundamentally different ways. Mass units express how many milligrams of the particle are present per unit volume. Molar units express how many particles are present, in nanomoles per litre. These measure different things, and there is no exact conversion between them.

The reason is the same length polymorphism that determines concentration. Because apolipoprotein(a) varies in size between individuals, particles differ in weight. Two people with identical particle numbers will have different masses if one carries a large isoform and the other a small one. Conversion factors circulate and are widely used, but they are population averages that can be substantially wrong for a given individual, particularly at the extremes of isoform size.

The field has moved towards reporting in molar units, because particle number is what relates most directly to risk and because a molar result is less affected by isoform size. Many laboratories still report mass, and thresholds quoted in guidance and in the literature appear in both.

Aspect	Mass reporting	Molar reporting
Unit	Milligrams per decilitre	Nanomoles per litre
What is counted	Total weight of particles	Number of particles
Affected by isoform size	Yes, substantially	Much less
Conversion to the other unit	Approximate only	Approximate only
Direction of travel in practice	Being phased out	Increasingly preferred
Risk relationship	Usable but noisier	More direct

The practical rule for anyone reading a result is to check the unit before comparing the number with any threshold. A value that looks alarming against a mass threshold may be unremarkable against a molar one and vice versa. Where a result is being compared with an earlier one, the comparison is only valid if both were reported in the same units by methods with comparable standardisation.

Isoform Size and Assay Standardisation

The size variation that complicates units also complicates the measurement itself, and this is the deeper technical problem in the field.

Lipoprotein(a) is measured by immunoassay, in which antibodies bind the particle and the amount of binding is converted into a concentration. The difficulty is where the antibodies bind. Many antibodies raised against apolipoprotein(a) recognise sites within the repeated region, and the number of those sites varies with isoform size. An antibody binding a repeated segment will therefore give a stronger signal per particle for a large isoform than for a small one, and the assay systematically overestimates concentration in people with large isoforms and underestimates it in people with small ones.

This matters clinically because small isoforms are associated with higher concentrations and higher risk. An assay biased in this way underestimates exactly the people who most need identifying.

The solution is assays using antibodies directed at parts of the protein present once per particle regardless of size, combined with calibration against reference material of known composition. Modern isoform-independent assays are substantially better than earlier generations, though full harmonisation across commercial platforms has not been achieved.

Two practical implications follow. Results from different laboratories or platforms may not be directly comparable, so a change between two measurements taken years apart on different systems should not be read as a biological change. And thresholds quoted in guidance were derived using particular assays, so applying them to another method carries some imprecision.

For most purposes this uncertainty is tolerable, because the clinical question is usually whether a level is clearly high, clearly low, or in an intermediate range, rather than whether it has moved by a small amount.

Who Benefits Most From Being Tested

There is genuine variation in guidance on whether everyone should be tested once or whether testing should be targeted, and the direction of movement has been towards broader testing.

The groups in which testing is most clearly worthwhile are reasonably consistent. Anyone with premature cardiovascular disease, meaning an event at an age younger than expected, particularly where conventional risk factors do not explain it. Anyone with a family history of premature cardiovascular disease. Anyone with a known or suspected familial cholesterol disorder, since the two conditions together produce risk substantially greater than either alone. First-degree relatives of a person with a known elevated level. And anyone whose calculated risk sits near a treatment threshold, where an additional piece of information could reasonably change the decision.

Progressive disease despite well-controlled conventional risk factors is another situation where the test adds real value, as is unexplained narrowing of the aortic valve, since lipoprotein(a) is associated with that process as well as with arterial disease.

The argument for testing everyone once rests on the combination of a common elevated level, an ordinary laboratory cost, a result that never needs repeating, and information that is directly relevant to relatives. The argument against rests on the limited options currently available to lower the level, which raises the question of what a person is expected to do with the result.

That objection is weaker than it first appears. Knowing that a person carries a substantially elevated level changes how aggressively other modifiable risk factors are managed, changes the threshold for starting lipid-lowering treatment, changes the intensity of blood pressure and glucose management, and identifies relatives who should be tested. It is actionable, even though the action is not aimed at the number itself.

Why Once in a Lifetime May Be Enough

Almost every other lipid measurement is repeated, because it changes. Lipoprotein(a) is the exception, and the reason is precisely the genetic determination described earlier.

The level reaches its adult value in childhood and remains broadly stable across decades. There is short-term biological variation, and there are situations that shift it temporarily, but there is no gradual drift comparable to what happens with LDL cholesterol over a lifetime. A measurement taken at thirty is generally a reasonable guide to the level at sixty.

This makes repeat testing largely uninformative. Where a repeat is reasonable is when the original result came from an older assay, when it was reported in units that cannot be compared with current thresholds, or when the value sat close enough to a decision threshold that confirmation is worthwhile.

There are circumstances that genuinely alter levels and are worth knowing about, because they can produce a misleading result. Lipoprotein(a) behaves in part as an acute phase reactant, rising during significant inflammation, infection or in the weeks after a major event such as a heart attack, so measuring it during or immediately after acute illness can overstate the usual level. Kidney disease, particularly with significant protein loss in the urine, raises it substantially. Thyroid dysfunction shifts it, and treating the thyroid problem returns it towards baseline. Pregnancy raises it temporarily. Some hormone therapies lower it modestly.

None of these change the underlying genetics, and the level returns to its set point once the situation resolves. A single result taken in a stable state is therefore usually all that is required, which makes it one of the few tests in cardiovascular medicine that can genuinely be done once and filed.

What Can and Cannot Currently Change It

This is the part that disappoints people, and it is worth being direct about.

Diet does not meaningfully lower lipoprotein(a). The dietary changes that reduce LDL cholesterol, particularly reducing saturated fat, have little effect on it and in some studies appear to move it slightly in the opposite direction. Exercise does not lower it. Weight loss does not lower it. Smoking cessation does not lower it, although it reduces overall cardiovascular risk substantially and remains worthwhile.

Among established medications, statins are the most important thing to understand. They do not lower lipoprotein(a) and may raise it slightly, which sometimes prompts people to question whether they should be taking them. The answer is that statins lower LDL cholesterol and reduce cardiovascular events in people with elevated lipoprotein(a) just as in others, so the small effect on this one particle does not offset the benefit. Some other lipid-lowering agents reduce it to varying degrees as a secondary effect, and niacin lowers it appreciably but has not been shown to improve outcomes and carries tolerability problems. Lipoprotein apheresis, a procedure that physically filters particles from blood, produces large reductions and is reserved for severe cases where disease is progressing despite everything else.

Therapies designed specifically to lower lipoprotein(a) are in clinical development, using approaches that reduce production of apolipoprotein(a) rather than clearing the particle after it forms. Large trials are underway to establish whether lowering the level reduces events, which is the question that has to be answered before such treatments enter routine use. Until those results exist, an elevated level is not treated directly.

What changes in response to the result is the management of everything else. An elevated level raises overall risk, which lowers the reasonable threshold for treating LDL cholesterol, blood pressure and glucose, and it strengthens the case for treating them to tighter targets. It also identifies relatives who should be tested, and it provides an explanation where one was missing. That is a smaller intervention than people hope for, and it is not nothing.

The reason this particle is worth knowing about is not that it is dramatic but that it is quietly common, invisible on the test most people receive, and stable enough to be settled permanently by a single measurement. If there is early heart disease in your family that nobody has ever explained, or if your own risk assessment sits awkwardly close to a decision point, it is a reasonable thing to ask about by name. The answer will not change next year, which is exactly what makes it worth having once.